Jeremy Bender
CIK: 0001863107
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (70 total)
- Jul 28, 2026BCAX
Bicara Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
39K shares- - Jul 7, 2026AURA
Aura Biosciences, Inc.
Award(A)Direct30K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect147.7K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect20.2K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect300K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Direct204.6K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect808.3K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect18.2K shares- - Apr 23, 2026DAWN
Day One Biopharmaceuticals, Inc.
Disposition(D)Indirect300K shares- - Feb 26, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
66K shares- - Feb 26, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectDeferred Restricted Stock Units
117.5K shares- - Feb 17, 2026DAWN
Day One Biopharmaceuticals, Inc.
Sale(S)Direct15.5K shares at avg. $11.60$179K - Feb 15, 2026DAWN
Day One Biopharmaceuticals, Inc.
Exercise(M)Direct11.7K shares- - Feb 15, 2026DAWN
Day One Biopharmaceuticals, Inc.
Exercise(M)Direct11.7K shares- - Feb 15, 2026DAWN
Day One Biopharmaceuticals, Inc.
Exercise(M)Direct14.8K shares- - Feb 15, 2026DAWN
Day One Biopharmaceuticals, Inc.
Exercise(M)Direct4.8K shares- - Jan 30, 2026DAWN
Day One Biopharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy Common Stock)
355K shares- - Jan 30, 2026DAWN
Day One Biopharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
237K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect300K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect300K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect7.2K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect7.2K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect300K shares- - Nov 25, 2025DAWN
Day One Biopharmaceuticals, Inc.
Gift(G)Indirect300K shares- - Nov 17, 2025DAWN
Day One Biopharmaceuticals, Inc.
Sale(S)Direct15.9K shares at avg. $8.91$142K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 28, 2026 |  BCAX Bicara Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 38,950 | - | - | Direct |
| Jul 7, 2026 |  AURA Aura Biosciences, Inc. | Award(A) | 30,000 | - | $0 | Direct |
| Apr 23, 2026 |  DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 147,702 | - | $0 | Indirect |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 20,204 | - | $0 | Indirect |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 300,000 | - | $0 | Indirect |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 204,643 | - | $0 | Direct |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 808,285 | - | $0 | Indirect |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 18,197 | - | $0 | Indirect |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Disposition(D) | 300,000 | - | $0 | Indirect |
| Feb 26, 2026 |  MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 66,000 | - | - | Direct |
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | Award(A) Deferred Restricted Stock Units | 117,533 | - | - | Direct |
| Feb 17, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Sale(S) | 15,459 | $11.60 | $179,338 | Direct |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Exercise(M) | 11,688 | - | $0 | Direct |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Exercise(M) | 11,687 | - | $0 | Direct |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Exercise(M) | 14,812 | - | $0 | Direct |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Exercise(M) | 4,750 | - | $0 | Direct |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Award(A) Stock Option (right to buy Common Stock) | 355,000 | - | - | Direct |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | Award(A) Restricted Stock Units | 237,000 | - | - | Direct |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 300,000 | - | - | Indirect |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 300,000 | - | - | Indirect |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 7,225 | - | - | Indirect |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 7,225 | - | - | Indirect |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 300,000 | - | - | Indirect |
| Nov 25, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Gift(G) | 300,000 | - | - | Indirect |
| Nov 17, 2025 | DAWN Day One Biopharmaceuticals, Inc. | Sale(S) | 15,894 | $8.91 | $141,690 | Direct |
1-25 of 70 transactions
About Bender Jeremy
Bender Jeremy (SEC CIK 0001863107) files insider reports with the SEC as Director of Bicara Therapeutics Inc. (BCAX), Director of Aura Biosciences, Inc. (AURA) and CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals, Inc. (DAWN). Signal8 also holds filings tied to 1 other company.
Signal8 holds 18 ownership filings by Bender Jeremy (2 Form 3, 16 Form 4), filed between Nov 19, 2024 and Jul 29, 2026. Those filings report 70 transactions, from Jul 2, 2024 to Jul 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bender Jeremy's filings is in BOSTON, MA.
Recent filings by Bender Jeremy
- Jul 28, 2026: Grant or award of BCAX derivative securities (Form 4, code A).
- Jul 7, 2026: Grant or award of AURA shares (Form 4, code A).
- Apr 23, 2026: Disposition to issuer transactions of DAWN shares (7 lines, Form 4, code D).
- Feb 26, 2026: Grants or awards of MREO derivative securities (2 lines, Form 4, code A).
- Feb 17, 2026: Open-market sale of DAWN shares (Form 4, code S).
Other insiders filing for Bicara Therapeutics Inc. (BCAX)
- Cohlhepp Ryan, President, COO & Interim CEO
- Larson Jennifer, Chief Financial Officer
- Hyep Ivan, Chief Financial Officer
- Mazumdar Claire, Chief Executive Officer
- Oliger Christy J., Director
- RA CAPITAL MANAGEMENT, L.P., Director